influenza
acut
respiratori
viru
infect
associ
signific
morbid
mortal
continu
threaten
global
public
health
guan
et
al
pales
tumpey
et
al
dawood
et
al
fraser
et
al
garten
et
al
innat
adapt
immun
system
play
critic
role
protect
influenza
virus
direct
manipul
host
immun
may
help
protect
individu
virus
inactiv
vaccin
season
influenza
virus
less
effect
novel
pandem
strain
eg
pandem
viru
hancock
et
al
although
may
provid
partial
crossprotect
medina
et
al
tu
et
al
commerci
avail
antivir
agent
adamantan
neuraminidas
inhibitor
target
specif
viral
protein
block
viru
uncoat
inhibit
viru
releas
infect
cell
respect
viral
mutat
allow
influenza
virus
evad
action
antivir
drug
lead
emerg
antivir
resist
lackenbi
et
al
dharan
et
al
layn
et
al
moscona
develop
altern
strategi
contain
viru
infect
boost
innat
immun
obviou
advantag
treatment
influenza
without
risk
encourag
antivir
resist
one
way
enhanc
innat
immun
stimul
nk
cell
activ
recent
studi
demonstr
influenza
viru
use
novel
strategi
evad
nk
cell
immun
directli
kill
antivir
drug
treat
influenza
emerg
antivir
resist
limit
avail
therapeut
option
furthermor
antivir
invari
effect
sever
influenza
caus
virus
mice
reconstitut
celldeplet
hupbmc
studi
provid
proofofconcept
novel
therapeut
strategi
treat
influenza
target
host
rather
viru
therebi
reduc
opportun
emerg
drugresist
virus
pam
commonli
use
treat
osteoporosi
paget
diseas
new
applic
old
drug
potenti
offer
safe
readili
avail
option
treat
influenza
recent
demonstr
ippexpand
cell
could
kill
human
season
influenza
kong
human
avian
influenza
virusinfect
monocytederiv
macrophag
mdm
qin
et
al
determin
whether
pamexpand
cell
similar
effect
virusinfect
cell
examin
cytolyt
activ
cocultur
pamexpand
cell
influenza
virusinfect
autolog
mdm
pam
select
expand
cell
vitro
fig
similar
previou
studi
cell
show
cytolyt
activ
mockinfect
mdm
depict
cell
display
potent
cytotox
virusinfect
mdm
fig
cell
significantli
inhibit
viru
replic
mdm
fig
addit
pamexpand
cell
also
display
similar
cytolyt
activ
influenza
viru
strain
b
virus
fig
use
neutral
antibodi
fasl
found
blockad
fasl
significantli
inhibit
cytolyt
activ
cell
virusinfect
mdm
fig
b
contrast
signific
chang
cytolyt
activ
nk
cell
inhibit
nk
cell
cytotox
therefor
look
altern
way
augment
innat
immun
anoth
cell
type
share
characterist
nk
cell
antigenpres
cell
play
critic
role
innat
adapt
immun
respons
infecti
agent
tumor
cell
card
egan
brand
et
al
poccia
et
al
born
et
al
konigshof
chien
eberl
moser
bonnevil
et
al
cell
constitut
lymphocyt
blood
peripher
organ
adult
human
anim
card
egan
shen
et
al
poccia
et
al
human
major
peripher
blood
lymphoid
organ
cell
cell
major
innatelik
peripher
cell
subset
card
egan
beetz
et
al
cell
specif
activ
hlaunrestrict
manner
small
nonpeptid
phosphoantigen
metabolit
isoprenoid
biosynthesi
pathway
beetz
et
al
isopentenyl
pyrophosph
ipp
intermedi
produc
mevalon
pathway
found
select
activ
expand
human
cell
vitro
vivo
bonnevil
scotet
puan
et
al
qin
et
al
pharmacolog
compound
aminobisphosphon
pamidron
pam
zoledron
commonli
use
treatment
osteoporosi
paget
diseas
induc
intracellular
accumul
ipp
lead
activ
expans
human
cell
bonnevil
scotet
bonnevil
et
al
urban
et
al
phosphoantigenexpand
cell
shown
antivir
activ
poccia
et
al
agrati
et
al
poccia
et
al
recent
demonstr
ippexpand
cell
potent
cytotox
activ
human
avian
influenza
virusinfect
cell
still
known
whether
pamexpand
cell
similar
effect
virusinfect
cell
wish
investig
role
cell
combat
influenza
viru
infect
vivo
howev
possibl
use
convent
mous
ferret
model
studi
murin
cell
express
homologu
sicard
et
al
bonnevil
scotet
born
et
al
whether
cell
exist
ferret
remain
unknown
studi
nonhuman
primat
constrain
high
cost
limit
avail
lack
genet
inbr
strain
suitabl
adopt
cell
transplant
pearson
et
al
studi
success
establish
human
mous
model
use
mice
human
peripher
blood
mononuclear
cell
hupbmc
demonstr
pam
effect
control
human
avian
influenza
viru
infect
protect
mice
death
boost
cell
immun
studi
suggest
novel
strategi
treatment
season
zoonot
pandem
influenza
use
pam
enhanc
host
cell
immun
mdm
infect
viru
moi
cultur
alon
vmdm
alon
purifi
pamexpand
cell
ratio
h
percentag
dead
mdm
among
target
cell
popul
identifi
four
differ
experi
shown
determin
viral
copi
virusinfect
mdm
cultur
alon
purifi
pamexpand
cell
h
total
rna
extract
cell
supernat
viral
matrix
gene
copi
quantifi
follow
revers
transcript
result
shown
viru
gene
copi
per
mdm
four
differ
experi
p
b
pamexpand
cell
cocultur
virusinfect
mdm
ratio
h
perforin
inhibitor
cma
granzym
b
inactiv
antitrail
atrail
antifasl
afasl
block
antibodi
relev
isotyp
control
use
cytotox
analyz
flow
cytometri
percentag
cell
popul
calcul
percentag
inhibit
rel
without
treatment
data
shown
mean
sem
repres
four
independ
experi
p
compar
relev
isotyp
control
mous
mous
gigg
goat
igg
ratio
revers
tabl
booster
vaccin
tetanu
toxoid
tt
mice
induc
human
b
cell
prolifer
ttspecif
secret
human
cell
serum
antittspecif
human
antibodi
vivo
fig
c
therefor
chimer
mice
function
human
b
cell
includ
similar
percentag
cell
wk
hupbmc
transplant
use
follow
experi
refer
human
mice
wildtyp
human
mice
infect
human
season
influenza
human
viru
intranas
human
viru
mouseadapt
strain
caus
obviou
diseas
wildtyp
mice
fig
fig
howev
induc
mild
diseas
mice
reconstitut
hupbmc
evid
weight
loss
day
infect
fig
b
mice
reconstitut
celldeplet
hupbmc
fig
show
compar
weight
loss
fig
b
use
adopt
transfer
human
cell
investig
antivir
activ
vivo
highli
purifi
pamexpand
cell
cellsmous
adopt
transfer
influenza
virusinfect
human
mice
iv
day
infect
consequ
frequenc
cell
peripher
blood
lymphocyt
human
mice
increas
peak
level
day
gradual
reduc
basal
level
day
infect
tabl
compar
pbstreat
mice
mice
receiv
pamexpand
cell
show
reduc
weight
loss
less
viru
replic
lung
fig
c
importantli
surviv
fig
e
result
mdm
trail
block
antibodi
treatment
fig
b
confirm
involv
cytolyt
granul
releas
kill
virusinfect
mdm
cell
perforinspecif
inhibitor
concanamycin
cma
granzym
b
inactiv
use
shown
fig
b
cytolyt
activ
cell
virusinfect
mdm
significantli
abrog
cma
treatment
treatment
fig
b
result
indic
cytotox
cell
depend
activ
mediat
fasfasl
perforingranzym
b
pathway
gener
human
mice
immunodefici
mice
determin
role
human
cell
influenza
infect
vivo
reconstitut
mice
human
peripher
mononuclear
cell
hupbmc
human
lymphocyt
stabli
engraft
mice
wk
transplant
stabl
engraft
maintain
wk
fig
day
transplant
nucleat
cell
peripher
blood
human
cell
cell
respect
fig
lymphocyt
popul
compris
cell
cell
cell
b
cell
nk
cell
cell
high
cell
other
fig
b
percentag
variou
human
lymphocyt
popul
mous
peripher
blood
compar
hupbmc
transplant
except
mice
mice
inject
pam
mgkg
bodi
weight
ip
signific
increas
human
cell
seen
peripher
blood
spleen
liver
lung
fig
b
importantli
consist
effect
human
kunzmann
et
al
pam
expand
cell
effect
cell
b
nk
cell
fig
c
addit
absenc
influenza
infect
signific
weight
chang
pamtreat
human
mice
compar
control
fig
result
indic
pam
select
expand
cell
human
mice
effect
weight
mice
next
investig
whether
pam
could
control
influenza
infect
diseas
human
mice
expand
cell
vivo
human
mice
infect
viru
inject
pam
pb
ip
day
infect
observ
adopt
transfer
experi
fig
treatment
pam
significantli
decreas
weight
loss
mortal
human
mice
fig
contrast
pam
effect
virusinfect
mice
cell
fig
b
human
mice
infect
human
season
pam
treatment
began
day
infect
complet
prevent
weight
loss
fig
c
human
season
viru
infect
kill
mice
effect
pam
indic
pamexpand
cell
help
control
influenza
infect
vivo
human
mice
contain
human
nk
cell
b
cell
fig
cell
enhanc
nk
cell
activ
mediat
adapt
immun
respons
brand
et
al
brand
et
al
maniar
et
al
antivir
activ
adopt
transfer
cell
may
associ
nk
cell
adapt
immun
exclud
possibl
transfer
highli
purifi
cell
virusinfect
mice
lack
human
murin
b
nk
cell
human
mice
frequenc
cell
peripher
blood
lymphocyt
mice
increas
peak
level
day
gradual
reduc
basal
level
day
infect
tabl
mice
adopt
transfer
pamexpand
cell
also
significantli
reduc
weight
loss
mortal
reduc
viru
replic
lung
compar
pbstreat
mice
fig
fh
data
demonstr
pamexpand
cell
effect
control
influenza
infect
vivo
consist
previou
studi
pam
could
select
expand
cell
human
kunzmann
et
al
da
et
al
also
found
pam
specif
expand
cell
cell
vitro
fig
determin
whether
occur
human
replic
human
season
viru
lung
day
onward
fig
pam
treatment
similarli
reduc
viru
titer
lung
human
mice
infect
avian
day
infect
fig
result
indic
pam
treatment
lead
control
viru
replic
lung
lung
human
mice
infect
human
season
avian
virus
differ
level
human
andor
murin
proinflammatori
cytokin
chemokin
tnf
rant
fig
b
fig
consist
find
previou
vitro
studi
primari
human
cell
cheung
et
al
avian
viru
induc
higher
level
human
tnf
murin
rant
lung
human
mice
compar
virusinfect
mice
fig
b
fig
pam
treatment
significantli
reduc
level
human
tnf
fig
murin
lung
human
virusinfect
human
mice
day
infect
fig
similarli
pam
significantli
decreas
level
human
tnf
fig
b
murin
tnf
rant
fig
lung
avian
virusinfect
human
mice
day
infect
furthermor
significantli
fewer
inflammatori
human
lymphocyt
ie
infiltr
less
patholog
lung
human
avian
virusinfect
pamtreat
human
mice
day
infect
compar
pbstreat
mice
infect
virus
fig
c
fig
collect
result
demonstr
pam
attenu
lung
inflamm
patholog
induc
virus
possibl
via
reduct
viral
replic
mortal
could
investig
wherea
cell
seen
lung
pamtreat
uninfect
human
mice
fig
b
accumul
cell
lung
virusinfect
human
mice
treat
pam
day
infect
significantli
higher
pbstreat
mice
fig
fig
result
indic
vivo
pamexpand
cell
move
infect
lung
exert
antivir
activ
importantli
treatment
pam
day
infect
significantli
reduc
weight
loss
mortal
caus
avian
influenza
avian
viru
fig
e
significantli
cell
accumul
avian
virusinfect
lung
treatment
pam
treatment
pb
fig
f
fig
indic
pamexpand
cell
also
migrat
infect
lung
exert
antivir
activ
avian
infect
mice
cell
pam
treatment
benefici
effect
mice
avian
infect
fig
g
observ
exclud
possibl
pam
direct
antivir
activ
without
pam
treatment
diseas
progress
faster
nonhuman
human
mice
fig
e
vs
fig
g
suggest
reconstitut
hupbmc
may
provid
protect
earli
stage
infect
collect
result
demonstr
pam
effect
reduc
influenza
diseas
sever
mortal
caus
human
avian
virus
human
mice
influenza
viru
replic
effect
lung
viral
titer
human
avian
virus
peak
day
infect
respect
fig
importantli
pam
treatment
significantli
suppress
b
accumul
cell
brown
differ
tissu
day
dose
pam
pb
repres
immunohistochem
section
spleen
liver
lung
intestin
uninfect
human
mice
stain
antihuman
mab
bar
c
repres
data
percentag
cell
b
nk
cell
peripher
blood
lymphocyt
day
dose
pam
pb
uninfect
human
mice
n
per
group
bodi
weight
chang
human
n
per
group
mice
n
per
group
pam
pb
treatment
day
data
repres
two
independ
experi
human
mice
celldeplet
hupbmc
fig
result
demonstr
antivir
effect
pam
influenza
viru
mainli
mediat
celldepend
mechan
studi
use
human
mice
demonstr
pam
treatment
effect
control
influenza
virusinduc
diseas
benefici
effect
mediat
boost
human
cell
immun
human
mice
wide
use
power
costeffect
anim
model
studi
human
innat
adapt
immun
infecti
diseas
ohashi
et
al
feuerer
et
al
stoddart
et
al
traggiai
et
al
jiang
et
al
pearson
et
al
exampl
chimer
human
pbmcscid
mice
use
studi
antibacteri
antitumor
effect
human
cell
kabelitz
et
al
beck
et
al
human
mice
establish
contain
function
human
b
cell
includ
similar
percentag
cell
peripher
blood
seen
human
fig
tabl
importantli
found
influenza
virus
could
effici
replic
caus
patholog
mice
determin
whether
antivir
role
pam
influenza
viru
mediat
cell
human
mice
human
mice
reconstitut
celldeplet
hupbmc
fig
use
mice
reconstitut
whole
hupbmc
celldeplet
hupbmc
infect
viru
inject
pam
pb
ip
day
infect
shown
fig
treatment
pam
significantli
decreas
weight
loss
mortal
human
mice
whole
hupbmc
fig
contrast
pam
effect
virusinfect
studi
show
pamexpand
cell
similar
antivir
activ
influenza
viru
fig
strain
b
virus
fig
importantli
use
adopt
transfer
vitroexpand
cell
influenza
virusinfect
immunodefici
human
mice
demonstr
first
time
cell
directli
inhibit
viral
replic
control
influenza
diseas
vivo
fig
consist
previou
report
aminobisphosphon
human
nonhuman
primat
kunzmann
et
al
sicard
et
al
report
pam
select
expand
cell
human
mice
fig
furthermor
demonstr
pam
inhibit
viral
replic
attenu
lung
inflamm
control
patholog
diseas
caus
influenza
select
activ
expans
cell
vivo
best
knowledg
first
demonstr
therapeut
effect
pam
influenza
infect
bukowski
et
al
battistini
et
al
bonnevil
born
et
al
found
pamexpand
cell
recogn
effici
kill
influenza
virusinfect
cell
thu
contribut
viru
clearanc
vitro
fig
cytotox
cell
influenza
virusinfect
cell
depend
activ
mediat
fasfasl
perforingranzym
b
pathway
fig
phosphoantigenexpand
cell
also
produc
larg
amount
antivir
cytokin
infiltr
inflammatori
lymphocyt
induct
proinflammatori
cytokin
chemokin
lung
weight
loss
sometim
death
fig
find
indic
human
mice
establish
suitabl
studi
human
cell
immun
respons
influenza
virus
bukowski
et
al
sciamma
blueston
battistini
et
al
poccia
et
al
scotet
et
al
vitro
studi
demonstr
broad
antivir
activ
human
cell
human
immunodefici
viru
hepat
b
viru
herp
simplex
viru
vaccinia
viru
human
cytomegaloviru
sar
coronaviru
kabelitz
et
al
poccia
et
al
poccia
et
al
sicard
et
al
previous
demonstr
hupbmc
wherea
pam
could
significantli
prevent
weight
loss
death
mice
reconstitut
whole
hupbmc
fig
therefor
data
unequivoc
demonstr
antivir
role
pam
influenza
viru
mainli
mediat
human
cell
contrast
origin
expect
absenc
cell
human
mice
may
allow
sever
diseas
develop
influenza
infect
seen
mice
reconstitut
whole
hupbmc
found
mice
reconstitut
either
whole
hupbmc
celldeplet
hupbmc
show
similar
diseas
sever
fig
b
probabl
effector
function
cell
depend
number
degre
activ
bonnevil
scotet
bonnevil
et
al
human
mice
contain
cell
fig
vitro
result
show
influenza
viru
alon
could
expand
cell
partial
activ
cell
presenc
pam
cell
fulli
activ
expand
number
express
suffici
perforin
granzym
b
protect
influenza
infect
fig
observ
human
beigel
et
al
cheung
et
al
differ
strain
influenza
viru
caus
vari
diseas
sever
human
mice
compar
human
season
viru
avian
viru
induc
sever
ill
pulmonari
patholog
even
death
human
mice
fig
fig
c
fig
avian
viru
led
higher
viral
load
induc
higher
level
proinflammatori
cytokin
chemokin
tnf
lung
fig
clear
whether
proinflammatori
cytokin
induct
simpli
reflect
enhanc
viral
replic
whether
contribut
immunopatholog
vitro
studi
primari
human
cell
shown
compar
season
influenza
virus
viru
intrins
caus
enhanc
cytokin
express
cheung
et
al
chan
et
al
human
mice
b
nk
cell
deriv
human
origin
wherea
lung
epitheli
cell
deriv
exclus
mous
origin
thu
influenza
infect
mice
associ
express
cytokineschemokin
human
mous
origin
fig
fig
human
cytokin
may
may
physiolog
activ
mous
lung
epithelium
perfect
model
influenza
pathogenesi
howev
human
mous
model
provid
relev
valuabl
model
studi
role
innatelik
cell
influenza
infect
effector
function
cell
requir
convent
antigen
present
context
mhc
bonnevil
scotet
urban
et
al
use
model
demonstr
expans
activ
cell
pam
effect
control
influenza
viru
diseas
notabl
human
season
viru
could
effici
infect
wildtyp
mice
success
infect
human
mice
indic
viru
replic
lung
signific
bodi
weight
loss
fig
poccia
et
al
consist
previou
report
avian
influenza
resist
antivir
effect
seo
et
al
also
found
secret
phosphoantigenexpand
cell
suppress
human
viru
replic
affect
avian
viral
replic
vitro
unpublish
data
found
pamexpand
cell
vivo
migrat
influenza
virusinfect
lung
human
mice
contribut
control
viru
replic
diseas
fig
fig
therefor
specul
influenza
viru
infect
human
mice
human
cell
activ
expand
pam
may
clear
human
virus
directli
kill
virusinfect
cell
secret
inhibit
viru
replic
infect
viru
clearanc
may
mainli
depend
direct
kill
lack
benefici
effect
pam
influenza
virusinfect
mice
exclud
possibl
drug
direct
antivir
effect
influenza
viru
vitro
studi
indic
pam
larg
expand
cell
expand
cell
number
cell
time
higher
cell
pam
stimul
fig
although
cell
could
also
activ
pam
frequenc
perforin
granzym
b
cell
cell
significantli
lower
cell
fig
inde
adopt
transfer
experi
mice
fig
fh
demonstr
pamexpand
cell
effect
control
influenza
infect
vivo
mice
lack
human
murin
b
nk
cell
importantli
also
found
pam
could
prevent
weight
loss
death
caus
influenza
viru
mice
reconstitut
celldeplet
figur
pam
control
influenza
diseas
human
mice
without
cell
celldeplet
hupbmc
obtain
doubl
deplet
cell
posit
select
magnet
microbead
mice
transplant
hupbmc
celldeplet
hupbmc
ip
healthi
human
donor
contrast
mice
reconstitut
whole
hupbmc
human
cell
mice
reconstitut
celldeplet
hupbmc
fig
human
mice
reconstitut
whole
hupbmc
pbmc
celldeplet
hupbmc
infect
viru
treat
pam
pb
day
infect
bodi
weight
chang
surviv
virusinfect
human
mice
n
per
group
shown
data
repres
two
independ
experi
deplet
cell
magnet
microbead
miltenyi
biotec
male
femal
mice
treat
liposom
vu
medisch
centrum
amsterdam
netherland
transplant
subleth
irradi
mice
transplant
ip
hupbmc
celldeplet
hupbmc
gener
hupbmc
buffi
coat
use
gener
human
mice
transplant
graftversushost
diseas
symptom
weight
loss
temperatur
chang
diarrhea
monitor
daili
immun
reconstitut
human
mice
examin
indic
time
manipul
perform
complianc
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
guidelin
use
experiment
anim
committe
use
live
anim
teach
research
hong
kong
human
influenza
viru
ahong
mouseadapt
influenza
avian
ahong
use
virus
cultur
madindarbi
canin
kidney
cell
describ
previous
tu
et
al
viru
titer
determin
daili
observ
cytopath
effect
cell
infect
serial
dilut
viru
stock
median
tissu
cultur
infect
dose
tcid
calcul
accord
reedmuench
formula
vitro
experi
day
mdm
infect
influenza
viru
multipl
infect
moi
h
viral
adsorpt
cell
wash
pb
remov
unadsorb
viru
human
mice
separ
mock
pbstreat
drugtreat
group
match
accord
sex
age
sourc
hupbmc
wk
transplant
hupbmc
establish
human
mice
infect
human
influenza
viru
tcid
viru
tcid
avian
influenza
ld
anesthesia
human
viru
infect
human
equival
dose
pam
mgkg
bodi
weight
pamisol
hospira
australia
pti
led
equival
volum
pb
inject
ip
day
viru
infect
avian
infect
pam
mgkg
bodi
weight
equival
volum
pb
inject
ip
day
viru
infect
surviv
monitor
infect
mice
weigh
daili
mice
weight
loss
sacrif
count
die
cytotox
assay
cell
effector
e
cocultur
virusinfect
mdm
target
et
ratio
h
afterward
nonadher
cell
harvest
directli
adher
cell
detach
trypsinedta
adher
nonadher
cell
stain
identifi
cell
ethidium
identifi
dead
cell
king
cytotox
cell
virusinfect
mdm
assess
flow
cytometri
percentag
cell
popul
quantif
flua
viral
copi
rtpcr
mdm
infect
viru
moi
h
later
unadsorb
viru
wash
away
care
mdm
cultur
alon
cell
h
cell
supernat
harvest
total
rna
extract
trizol
ls
reagent
accord
manufactur
instruct
invitrogen
cdna
synthes
oligo
dt
primer
superscript
ii
revers
transcript
invitrogen
viral
matrix
gene
copi
quantifi
basi
sybr
green
fluoresc
signal
pcr
forward
primer
revers
primer
abi
prism
sequenc
detect
system
appli
biosystem
qin
et
al
result
express
number
target
gene
copi
per
mdm
block
assay
cell
e
cocultur
virusinfect
mdm
et
ratio
h
neutral
antibodi
bd
antifasl
fig
importantli
avian
viru
human
season
viru
could
infect
human
mous
cell
lung
human
mice
fig
suggest
process
human
may
alter
lung
tissu
tropism
influenza
viru
mice
need
investig
examin
express
viru
receptor
respiratori
tract
lung
human
mice
signific
target
cell
rather
influenza
viru
lie
innatelik
effector
function
allow
exhibit
antivir
activ
rapidli
regardless
viru
subtyp
emerg
drugresist
strain
use
human
equival
dose
pam
effect
control
influenza
diseas
human
mice
suggest
feasibl
translat
human
clinic
trial
sever
protocol
base
vivo
activ
cell
phosphoantigen
aminobisphophon
develop
treatment
certain
tumor
bacteri
infect
bonnevil
scotet
caccamo
et
al
dieli
et
al
huang
et
al
bonnevil
et
al
summari
studi
demonstr
pam
control
influenza
infect
human
mice
inhibit
viru
replic
associ
attenu
inflamm
lung
boost
human
cell
benefici
effect
activ
virus
vari
subtyp
virul
find
confirm
proof
principl
novel
therapeut
approachus
pam
boost
human
cell
immun
season
zoonot
pandem
influenza
virus
studi
deserv
extend
human
clinic
trial
pam
commonli
use
clinic
treatment
osteoporosi
paget
diseas
new
applic
old
drug
potenti
offer
safe
readili
avail
option
either
alon
combin
convent
antivir
drug
treatment
influenza
especi
combat
pandem
drugresist
virus
pbmc
isol
buffi
coat
health
donor
hong
kong
red
cross
ficollhypaqu
pharmacia
gradient
centrifug
previous
describ
tu
et
al
research
protocol
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
pbmc
cultur
fb
medium
pam
recombin
human
invitrogen
ad
final
concentr
iuml
everi
day
cultur
cell
purifi
neg
select
tcr
cell
isol
kit
accord
manufactur
instruct
miltenyi
biotec
human
mdm
gener
mononuclear
cell
previous
describ
zhou
et
al
brief
adher
monocyt
seed
flatbottom
plate
cellswel
plate
cellswel
refe
supplement
autolog
serum
allow
differenti
macrophag
puriti
monocyt
determin
flow
cytometri
monoclon
antibodi
consist
gener
human
mice
mice
purchas
tacon
maintain
laboratori
anim
unit
univers
hong
kong
establish
human
mice
model
hupbmc
isol
buffi
coat
prepar
blood
healthi
donor
hong
kong
red
cross
celldeplet
hupbmc
obtain
onlin
supplement
materi
fig
demonstr
pam
select
expand
human
cell
vitro
fig
indic
pamexpand
cell
display
cytolyt
activ
influenza
b
virus
fig
show
gener
human
mice
mice
hupbmc
fig
demonstr
human
viru
infect
wildtyp
mice
fig
show
gener
human
mice
celldeplet
hupbmc
fig
show
number
cell
lung
virusinfect
human
mice
treatment
pam
fig
show
effect
pam
murin
proinflammatori
cytokin
chemokin
virusinfect
lung
human
mice
fig
show
patholog
score
infiltr
human
lung
human
avian
virusinfect
pamtreat
human
mice
infect
fig
demonstr
pam
enhanc
influenza
virusstimul
cell
activ
express
perforin
granzym
b
fig
show
human
avian
virus
infect
human
murin
cell
lung
human
mice
tabl
show
percentag
peripher
blood
lymphocyt
subset
transplant
human
mice
tabl
show
frequenc
cell
peripher
blood
lymphocyt
mice
adopt
transfer
cell
onlin
supplement
materi
avail
http
immun
wk
transplant
hupbmc
establish
human
mice
prime
limit
floccul
lf
tt
vaccin
adventispasteur
subcutan
inguin
pouch
region
booster
vaccin
lf
tt
given
right
hind
footpad
wk
prime
number
human
cell
cell
b
cell
mous
peripher
blood
count
fac
analysi
cell
cell
peripher
blood
analyz
intracellular
cytokin
stain
serum
ttspecif
antibodi
examin
elisa
flow
cytometr
analysi
cell
stain
surfac
marker
follow
antibodi
bd
invitrogen
intracellular
stain
cell
fix
permeabil
stain
antiperforin
pfp
antigranzym
b
grb
antibodi
bd
relev
isotyp
control
describ
previous
tu
et
al
zheng
et
al
sampl
acquir
facsaria
bd
analyz
flowjo
softwar
tree
star
elisa
assay
concentr
total
human
igg
ttspecif
igg
serum
human
mice
determin
quantit
elisa
set
bethyl
laboratori
inc
lung
infect
human
mice
harvest
indic
time
homogen
ml
pb
centrifug
g
min
supernat
collect
determin
viru
titer
inflammatori
cytokin
chemokin
concentr
human
murin
cytokin
chemokin
detect
analyz
human
cytokin
chemokin
assay
kit
bender
medsystem
immunohistochemistri
assay
lung
lung
liver
spleen
kidney
intestin
mice
human
mice
harvest
indic
time
fix
formalin
maintain
ethanol
section
prepar
accord
standard
protocol
stain
hematoxylin
eosin
antihuman
antihuman
abcam
antihuman
antibodi
clone
gift
bonnevil
e
scotet
institut
nation
de
la
et
de
la
recherch
pari
franc
visual
hrppolym
antimouserabbit
ihc
kit
maxvis
china
histopatholog
score
number
cell
lung
tissu
analyz
two
independ
observ
blind
treatment
lung
tissu
section
screen
five
field
mous
select
randomli
histopatholog
score
evalu
previous
describ
dybe
et
al
sever
grade
scale
normal
mild
moder
sever
nucleat
cell
area
count
magnif
express
number
cell
per
field
kuang
et
al
data
mean
sem
multipl
regress
analysi
use
test
differ
bodi
weight
chang
pb
celltreat
pamtreat
group
adjust
time
infect
differ
cell
death
viral
copi
vitro
experi
viral
titer
concentr
proinflammatori
cytokineschemokin
pb
celltreat
pamtreat
group
analyz
unpair
twotail
student
test
p
valu
differ
surviv
determin
kaplanmei
logrank
test
p
consid
signific
